Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event

Related Experiment Video

Updated: Jun 18, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Shotaro Ide1, Hiroshi Soda, Tomoaki Hakariya

  • 1Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan.

Lung Cancer (Amsterdam, Netherlands)
|November 10, 2009
PubMed

Insights

Sorafenib, a cancer drug, may cause severe interstitial lung disease, particularly in Japanese patients. This rare but serious side effect requires careful monitoring during treatment for metastatic renal cell carcinoma.

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Sorafenib is a targeted therapy used for metastatic renal cell carcinoma.
  • Interstitial lung disease (ILD) is a known class effect of some tyrosine kinase inhibitors.
  • Previous literature has not reported ILD specifically associated with sorafenib.

Observation:

  • A post-marketing survey in Japan identified 4 cases of interstitial pneumonia among ~2,000 sorafenib-treated patients.
  • This study details a specific case of a Japanese patient experiencing severe interstitial pneumonia.
  • The patient received sorafenib for metastatic renal cell carcinoma.

Findings:

  • Sorafenib treatment is strongly suspected as the cause of severe interstitial pneumonia in this patient.
  • The incidence of sorafenib-induced ILD may be higher in Japanese populations.
  • This suggests potential racial differences in drug-induced lung toxicity.

Implications:

  • Oncologists should be vigilant for potential sorafenib-induced interstitial lung disease.
  • Awareness is crucial for patients undergoing sorafenib therapy, especially those of Japanese ethnicity.
  • Future clinical trials involving sorafenib, particularly for lung cancer, must consider this potential adverse event.

Related Concept Videos

Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...